A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 789-795

  Schaar, Dale ^a   Goodell, Lauri ^a   Aisner, Joseph ^a   Cui, Xiao Xing ^b   Han, Zheng Tao ^c   Chang, Richard ^b   Martin, John ^a   Grospe, Stephanie ^a   Dudek, Liesel ^a   Riley, Joan ^a   Manago, Jacqueline ^a   Lin, Yong ^a   Rubin, Eric H ^a   Conney, Allan ^b   Strair, Roger K ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Henan Tumor Research Institute   (China)

Author keywords

12 O tetradecanoylphorbol 13 acetate; Phorbol esters

Indexed keywords

ALKALINE PHOSPHATASE; PHORBOL 13 ACETATE 12 MYRISTATE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; BIOASSAY; CANCER PATIENT; CANCER RELAPSE; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; EXTRAVASATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRAND MAL SEIZURE; HEADACHE; HEMATURIA; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY CARCINOMA; LEUKEMIA RELAPSE; LOW BACK PAIN; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PAIN; PETECHIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; RESPIRATORY DISTRESS; RHINITIS; RIGOR; SKIN CARCINOMA; SORE THROAT; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; URTICARIA; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 33645731655     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0125-1     Document Type: Article

References (41)

1. Huberman E, Callaham MF (1979) Induction of terminal differentiation in human promyelocytic leukemia cells by tumor promoting agents. Proc Natl Acad Sci USA 76:1293-1297
2. Lotem J, Sachs L (1979) Regulation of differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc Natl Acad Sci USA 76:5158-5162
3. Rovera G, Santoli D, Damsky C (1979) Human promyelocytic cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 76:2779-2783
4. Koeffler HP (1980) Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. J Clin Invest 66:1101-1108
5. Koeffler HP, Bar-Eli M, Territo MC (1981) Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation. Cancer Res 41:919-926
6. Polliack A, Leizerowitz R, Korkesh A, Gurfel D, Gamliel H, Galili U (1982) Exposure to TPA in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias. Am J Hematol 13:199-211
7. Shkolnick T, Schlossman SF, Griffin JD (1985) Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester. Leuk Res 9:11-17
8. Abrahm JL, Gerson SL, Hoxie JA, Tannenbaum SH, Cassileth PA, Cooper RA (1986) Differential effects of phorbol esters on normal myeloid precursors and leukemic cells. Cancer Res 46:3711-3716
9. Hofmann J (1997) The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11:649
10. Mochly-Rosen D, Kauvar LM (1998) Modulating protein kinase C signal transduction. Adv Pharmacol 44:91
11. Newton AC (1995) Protein kinase C structure, function and regulation. J Biol Chem 270:28495
12. Kazanietz MG (2000) Eyes wide shut: protein kinase C isoenzymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 28:5
13. Hunter T (2000) Signaling 2000 and beyond. Cell 100:113
14. Meinhardt G, Roth J, Hass R (2000) Activation of protein kinase C relays distinct signaling pathways in the same cell type: differentiation and caspase-mediated apoptosis. Cell Death Differ 7:795-803
15. Garrington TP, Johnson GL (1999) Organization and regulation of MAPK signaling pathways. Curr Opin Cell Biol 11:211
16. Vojtek AB, Der CJ (1998) Increasing complexity of the ras signaling pathway. J Biol Chem 273:19925
17. Hill CS, Treisman R (1995) Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80:199
18. Treisman R (1996) Regulation of transcription by MAP kinase casacades. Curr Opin Cell Biol 8:205
19. Schwartz MA, Baron V (2000) Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol 11:197
20. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCunbrey JA (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263-1293
21. Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101:4667-4679
22. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal regulated kinase activation. Cell 80:179
23. Keyse SM (2000) Protein phosphatases and the regulation of MAPK signaling. Curr Opin Cell Biol 12:186
24. Bhalla US (2004) Models of cell signaling pathways. Curr Opin Genet Dev 14:375-381
25. Mochly-Rosen D, Kauvar LM (2000) Pharmacologic regulation of network kinetics by protein kinase C localization. Semin Immunol 12:55
26. Mochly-Rosen D, Gordon AS (1998) Anchoring proteins for protein kinase C: a means for isozyme specificity. FASEB J 12:35
27. Kelly L, Clark J, Gilliland DG (2002) Comprehensive genotypic analysis of leukemia:clinical and therapeutic implications. Curr Opin Oncol 14:10
28. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R (1999) Prognostic implications of Flt-3 and N-ras gene mutations in acute myeloid leukemia. Blood 93:3074-3080
29. Beaupre DM, Kuzrock R (1999) RAS and leukemia. J Clin Oncol 17:1071-1079
30. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H (1997) Constitutive activation of the mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11:479-484
31. Kim S-C, Hahn J-S, Min Y-H, Yoo N-C, Ko Y-W, Lee W-J (1999) Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal regulated kinase, and down-regulation of a phosphatase, PAC1. Blood 93:3893
32. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T (2000) Tandem duplicated Flt-3 constitutively activates STA5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631
33. Morgan MA, Dolp O, Reuter WM (2001) Cell cyle dependent activation of mitogen-activated protein kinase kinase (MEK-1/ 2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97:1823
34. Schaar DG, Liu H, Sharma S, Ting Y, Martin J, Krier C, Ciardella M, Osman M, Goodell L, Notterman DA, Strair RK (2005) 12-O-Tetradecanoylphorbol-13- acetate (TPA)-induced dual-specificity phosphatase expression and AML cell survival. Leuk Res 29:1171-1179
35. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS, Newmark HL, Conney AH, Chang RL (1998) Effect of intravenous 12-O-tetradecanoylphorbol-13- acetate (TPA) in patients with myelocytic leukemia:preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 95:5357-5361
36. Strair RK, Schaar D, Goodell L, Aisner J, Chin K-V, Eid J, Senzon R, Knox B, Cui XX, Han ZT, Newmark HL, Rabson AB, Chang RL, Conney A (2002) Administration of a phorbol ester to patients with hematologic malignancies: Preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol- 13-acetate. Clin Cancer Res 8:2512-2518
37. Cui XX, Chang RL, Zheng X, Woodward D, Strair R, Conney A (2002) A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13- acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 13:169-174
38. Han ZT, Tong YK, He LM, Zhang Y, Sun JZ, Wang TY, Zhang H, Cui YL, Newmark H, Conney AH, Chang R (1998) 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci USA 95:5362-5365
39. Therasse P, Arbuck SG, Eisenhauer EA (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 92:205-216
40. Zheng X, Chang RL, Cui XX, Kelly KA, Shih WJ, Lin Y, Strair R, Suh J, Han ZT, Rabson A, Conney AH (2001) Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 12:419-427
41. Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A, Conney AH (2004) Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64:1811-1820